EGFR and neoplasm: developed novel TPGS‐MA‐CH solid lipid nanoparticles that enhanced drug targeting and bioavailability to tumor tissues by significantly down‐regulating EGFR and Akt phosphorylation and EGFR expression in A549 cells.